Mitogens and the Cell Cycle
Cancer
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Tumor Progression
Targeted Cancer Therapies
Combination Therapies and Personalized Medicine
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 15, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Eric S Kim1, David J Stewart2, Alok A Khorana3
1James P. Wilmot Cancer Center, and the Department of Medicine, University of Rochester, Rochester, NY, USA.
No abstract available in PubMed .
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023